Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

90.27 +1.84 (+2.08%)
Streaming Delayed Price Updated: 11:35 AM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Kymera Stock Up 130% as $135 Million Buy Boosts Immunology Bet ↗
Kymera Therapeutics develops targeted protein degradation therapies for immunology, oncology, and fibrosis using proprietary technology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs. 
Via The Motley Fool
News headline image
Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks ↗
Via MarketBeat
News headline image
Streaming Wars Go Hostile Just as Wall Street Braces for the Fed ↗
Stocks slipped from record levels on Monday as investors shifted into “wait-and-see” mode ahead of Wednesday’s Fed decision. At the same time, Hollywood turned into a live-fire M&A battlefield, with... 
Via Chartmill
Topics Economy
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
What to Expect from Kymera Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
What 6 Analyst Ratings Have To Say About Kymera Therapeutics ↗
 
Via Benzinga
News headline image
What's going on in today's session ↗
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
Via Chartmill
News headline image
Wondering what's happening in today's pre-market session? ↗
Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
Why Is KYMR Stock Up 30% Pre-Market Today? ↗
Kymera Therapeutics stated that its BroADen clinical trial of KT-621 showed that it achieved median reductions of STAT6 degradation of 94% and 98% in skin and blood in 100mg and 200mg dose groups. 
Via Stocktwits
Topics Economy
News headline image
These stocks are moving in today's after hours session ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
Kymera (KYMR) Q3 2025 Earnings Call Transcript ↗
Kymera (KYMR) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
10 Analysts Have This To Say About Kymera Therapeutics ↗
 
Via Benzinga
News headline image
Kymera Therapeutics Inc (NASDAQ:KYMR) Q3 2025 Earnings: Clinical Progress Overshadows Financial Miss ↗
Kymera Therapeutics stock rises on positive clinical updates for its atopic dermatitis drug, KT-621, despite missing Q3 2025 revenue and EPS estimates. 
Via Chartmill
News headline image
The Analyst Verdict: Kymera Therapeutics In The Eyes Of 6 Experts ↗
 
Via Benzinga
News headline image
Breaking Down Kymera Therapeutics: 4 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
This Chubb Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Kymera Therapeutics Inc (NASDAQ:KYMR) Reports Q2 2025 Earnings Miss, Stock Dips Pre-Market ↗
Kymera Therapeutics Q2 2025 earnings miss estimates with $11.48M revenue (-55% YoY) and $0.95 EPS loss. Stock drops 2.7% pre-market despite clinical progress in STAT6 candidate. 
Via Chartmill
Topics Earnings
News headline image
Kymera Revenue Drops 55 Percent in Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades' ↗
Insights from strategists and analysts can greatly influence market sentiment and investment strategies. CNBC's Halftime Report Final Trades discussed SNV, IYF, NEE-PR, and GILD. 
Via Benzinga
News headline image
Beyond The Numbers: 8 Analysts Discuss Kymera Therapeutics Stock ↗
 
Via Benzinga
News headline image
Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 11, 2025 ↗
 
Via Benzinga
News headline image
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit ↗
Under the terms of the agreement, Kymera is eligible to receive up to $750 million in total payments, including up to $85 million in upfront and potential option exercise payments. 
Via Stocktwits
News headline image
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies ↗
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases. 
Via Benzinga
News headline image
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
Three relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development. 
Via MarketBeat
News headline image
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio? ↗
 
Via Benzinga
News headline image
Signet Posts Upbeat Earnings, Joins Ferguson Enterprises, Dollar General And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Disney To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.